Selected liposomal products in clinical development in GI cancers
| Conditions | Intervention | Phase | Sponsor | Clinical Trials Identifier |
|---|---|---|---|---|
| Advanced colorectal cancer | CPX-1 (irinotecan HCl: floxuridine) | II | Jazz Pharmaceuticals (Dublin, Republic of Ireland) | NCT00361842 |
| Gemcitabine-resistant metastatic pancreatic cancer | Liposomal irinotecan (Onivyde) | III (Approved 2015) | Merrimack Pharmaceuticals | NCT01494506 |
| Gastric, gastroesophageal, and esophageal adenocarcinoma | Oxaliplatin in transferrin-conjugated liposome | I/II | Mebiopharm Co., Ltd. (Tokyo, Japan) | NCT00964080 |
| Nonresectable hepatocellular carcinoma | ThermoDox (thermally sensitive liposomal doxorubicin) | III | Celsion (Lawrenceville, NJ) | NCT02112656 |
| Locally advanced/metastatic pancreatic cancer | EndoTAG-1 (paclitaxel in cationic liposomes) | III | SynCore Biotechnology Co., Ltd. (Chung Shan Village, Taiwan) | NCT03126435 |
| Pancreatic cancer | (LE-DT) docetaxel | II | INSYS Therapeutics Inc. (Phoenix, AZ) | NCT01186731 |
| Metastatic/unresectable GI cancers | Liposomal irinotecan | I/II | Emory University (Atlanta, GA) | NCT03368963 |
| Liver cancer | Liposomal doxorubicin with TTFields (alternating electric fields) | I | MD Anderson Cancer Center (Houston, TX) | NCT03203525 |
| Liver cancer | MTL-CEBPA (CEBPA small activating RNA in liposomes | I | Mina Alpha Ltd. (London, UK) | NCT02716012 |
| Metastatic colorectal cancer | SN-38 liposome | II | Alliance for Clinical Trials in Oncology (Boston, MA) | NCT00311610 |
| Solid tumors including gastric/gastroesophageal/pancreatic ductal adenocarcinoma | (MM-310) docetaxel in liposomes targeted with antibodies to EphA2 receptor | I | Merrimack Pharmaceuticals | NCT03076372 |
| Locally advanced/metastatic esophageal carcinoma | PNU-93914 (liposomal paclitaxel) | II | Memorial Sloan-Kettering Cancer Center (New York, NY) | NCT00016900 |
| Metastatic pancreatic cancer | SGT-53 (human p53 plasmid DNA in cationic liposome) | II | SynerGene Therapeutics, Inc. (Potomac, MD) | NCT02340117 |
| Primary liver cancer | MRX34 (liposomal miRNA-34a mimic) | I | Mirna Therapeutics, Inc. (Austin, TX) | NCT01829971 |
| Metastatic pancreatic cancer | Atu027 (liposomal protein kinase N3 siRNA) | I/II | Silence Therapeutics GmbH (Berlin, Germany) | NCT01808638 |